ReviewCurrent hypertension reports2005
Differential effects of antihypertensive drugs on new-onset diabetes?
Review in Current hypertension reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 24 citations in OpenAlex.
- Observational
- A retrospective longitudinal cohort study of antihypertensive drug use and new-onset diabetes in Taiwanese patients.BioMed research international · 2013Article
- The potential role of clinical pharmacy services in patients with cardiovascular diseases.The journal of Tehran Heart Center · 2012Article
- Beta-blockers in hypertension: truths and half-truths.Journal of clinical hypertension (Greenwich, Conn.) · 2008Article
- Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?Vascular health and risk management · 2007Review
- A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.Journal of clinical hypertension (Greenwich, Conn.) · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the late 1950s, new-onset diabetes has been a recognized adverse effect of some antihypertensive drugs. Although diagnostic criteria for diabetes mellitus have changed greatly since then, epidemiologic and physiologic studies suggest that there are differences in glucose tolerance and incident diabetes across antihypertensive drug classes. Data about incident diabetes are now available from 16 long-term, randomized, clinical trials of antihypertensive drugs. From traditional meta-analyses, the rank-ordering of the drug classes is: beta-blocker approximately thiazide diuretic > placebo approximately calcium antagonist > angiotensin-converting enzyme (ACE) inhibitor approximately angiotensin receptor blocker (ARB). Earlier studies indicated that most individuals who developed incident diabetes were "pre-diabetic" before beginning antihypertensive therapy, and ipso facto had increased cardiovascular risk compared with individuals with normal glucose tolerance. An earlier diagnosis of diabetes mellitus generally has little impact (over 5 years) on cardiovascular risk. The clinical importance of differential effects of antihypertensive drugs on incident diabetes is, therefore, much less clear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.